Sectra Acquires Oxipit, Advancing Autonomous AI Capabilities in Diagnostic Imaging

International medical imaging IT and cybersecurity company Sectra has agreed to acquire Oxipit, UAB, a Lithuanian company specialising in AI-based solutions for radiology. Oxipit holds the first CE Class IIB certification for autonomous AI in chest X-ray analysis. The transaction is subject to customary closing conditions and is expected to be completed during March 2026.

Most AI in radiology today acts as decision support, flagging findings, suggesting measurements, or assisting prioritisation. These tools support radiologists but do not replace any part of the reporting process. Autonomous AI represents a different model. It is developed and validated to independently complete a specific diagnostic task under controlled clinical conditions. The scope of autonomy is clearly defined, performance thresholds are rigorously validated, and use is governed by regulatory approval.

Oxipit's ChestLink is a leading example of this autonomous approach. Within its defined clinical scope, it is designed to automatically identify and clear high-confidence normal chest X-ray examinations from the radiologist's worklist. This allows radiologists to focus their expertise on cases with a higher probability of disease. By safely reducing routine workload, this model directly addresses the growing challenge of rising imaging volumes and persistent workforce constraints, while operating under rigorously validated safety thresholds. ChestLink holds CE Class IIb certification, reflecting the elevated regulatory and clinical validation standards required for autonomous AI applications in healthcare.

ChestLink is already available through the Sectra Amplifier Marketplace for AI, supporting seamless integration into existing radiology workflows.

"The ability to autonomously clear high-confidence normal cases marks a transformative step for radiology. By combining clinical confidence with intelligent automation, we can expand capacity, reduce radiologist workload, and generate substantial financial benefits through higher productivity and lower cost. We look forward to continuing to sell Oxipit products in Europe and advancing the necessary regulatory approvals to bring it to more markets worldwide," says Torbjörn Kronander, President and CEO of Sectra.